3alpha-hydroxysteroid 3-dehydrogenase (Re-specific)

This is an abbreviated version!
For detailed information about 3alpha-hydroxysteroid 3-dehydrogenase (Re-specific), go to the full flat file.

Word Map on EC


a 3alpha-hydroxysteroid
a 3-oxosteroid


17beta-HSD type 5, 17beta-hydroxysteroid dehydrogenase type 5, 3-alpha hydroxysteroid oxidoreductase, 3-alpha-HSO, 3alpha-HSD, 3alpha-HSD type 2, 3alpha-HSD type 3, 3alpha-HSD/CR, 3alpha-HSD3, 3alpha-HSOR, 3alpha-hydroxysteroid dehydrogenase, 3alpha-hydroxysteroid dehydrogenase (B-specific), 3alpha-hydroxysteroid dehydrogenase type 2, 3alpha-hydroxysteroid dehydrogenase/carbonyl reductase, 3alpha-hydroxysteroid oxido-reductase, 3alpha-hydroxysteroid oxidoreductase, 3alpha-hydroxysteroid:NAD(P) oxidoreductase, 3alphaHSD, A-specific 3alpha-hydroxysteroid dehydrogenase, AKR1C17, AKR1C2, AKR1C3, AKR1C4, AKR1C9, alpha-HSD/CR, B-specific 3alpha-hydroxysteroid dehydrogenase, bile acid-binding protein, DD2, dihydrodiol dehydrogenase, HSDH, More, NAD+-dependent 3alpha-HSD, NADP(H)-dependent 3alpha-HSD, type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase, type 3 3-alpha-hydroxysteroid dehydrogenase, type 3 3alpha-HSD, type 3 3alpha-hydroxysteroid dehydrogenase, type 5 beta-hydroxysteroid dehydrogenase


     1 Oxidoreductases
         1.1 Acting on the CH-OH group of donors
             1.1.1 With NAD+ or NADP+ as acceptor
       3alpha-hydroxysteroid 3-dehydrogenase (Re-specific)


Crystallization on EC - 3alpha-hydroxysteroid 3-dehydrogenase (Re-specific)

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
10 ns molecular dynamics simulations of inhibitor bound to isofrom AKR1C3. Binding could induce conformational changes to both inhibitor and enzyme. The compound presumably assumes a stable, energetically favored, planar conformation, with an estimated free energy of binding of -5 kcal/mol
docking of inhibitors (2E)-3-(4-methylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid, (2E)-3-(4-ethylphenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid, (2E)-3-(4-bromophenyl)-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid and (2E)-3-[4-(methylsulfanyl)phenyl]-2-[4-(methylsulfonyl)phenyl]prop-2-enoic acid to crystal structure. Compounds occupy a similar position of the active site as the co-crystallized indomethacin, with the Aryl1 overlapping with the p-chlorobenzoyl moiety of the indomethacin and the Aryl2 overlapping with an indole part of the indomethacin
in complex with 3-phenoxybenzoic acid, to 1.68 A resolution, space group P212121
in complex with inhibitor 1-(4-[[(2R)-2-methylpiperidin-1-yl]sulfonyl]phenyl)-1,3-dihydro-2H-pyrrol-2-one. The 2-pyrrolidinone does not interact directly with residues in the oxyanion hole
in complex with inhibitor 3-[[4-(trifluoromethyl)phenyl]amino]benzoic acid. Compound adopts a similar binding orientation as flufenamic acid, however, its phenylamino ring projects deeper into a subpocket and confers selectivity over the other AKR1C isoforms
purified recombinant wild-type enzyme, hanging drop vapour diffusion method, 4°C, mixing of equal volumes of 14 mg/ml protein solution and mother liquor containing 0.1 M sodium citrate, pH 6.5, 0.1 M ammonium acetate, and 24-30% PEG 4000, cryoprotection of crystals in 20% ethylene glycol in mother liquor, X-ray diffraction structure determination and analysis at 1.9 A resolution, molecular replacement study
purified enzyme with NADH, hanging drop vapour diffusion method, 4°C, in presence of 1.4 M ammonium sulfate, 0.14 M NaCl, and 0.1 M Tris, pH 9.0, rod cluster crystals appear within 1 week, X-ray diffraction structure determination and analysis at 1.8 A resolution, modeling
vapor diffusion techniques using ammonium sulfate as precipitant